These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38358005)

  • 1. Treatment of Cutaneous Leishmaniasis lesion caused by Leishmania major Using Leech Therapy in BALB/c Mice.
    Shirani-Bidabadi L
    J Vector Borne Dis; 2024 Feb; ():. PubMed ID: 38358005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal leech therapy-an overall perspective.
    Sig AK; Guney M; Uskudar Guclu A; Ozmen E
    Integr Med Res; 2017 Dec; 6(4):337-343. PubMed ID: 29296560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone Effects Against Cutaneous Leishmaniasis Caused by
    Azizi H; Mahdavinik E; Hataminejad M; Khamesipour A; Montazeri S
    Infect Disord Drug Targets; 2023; 23(6):e020623217598. PubMed ID: 37278044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946.
    Rahimi S; Rafinejad J; Akhavan AA; Ahmadkhaniha R; Bakhtiyari M; Khamesipour A; Akbarzadeh K
    Parasit Vectors; 2023 Feb; 16(1):72. PubMed ID: 36797798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
    Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL
    Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hydroalcoholic extract of
    Sarkari B; Mohseni M; Moein MR; Shahriarirad R; Asgari Q
    Int J Appl Basic Med Res; 2017; 7(1):53-56. PubMed ID: 28251109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
    Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
    Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of sodium selenite and zinc sulphate as supplementary with meglumine antimoniate( glucantime®) against cutaneous leishmaniasis in BALB/c mice.
    Sorkhroodi FZ; Naeini AA; Ramazani AZ; Ghazvini MA; Mohebali M; Keshavarz S
    Iran J Parasitol; 2010 Sep; 5(3):11-9. PubMed ID: 22347250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
    Jabini R; Jaafari MR; Vahdati Hasani F; Ghazizadeh F; Khamesipour A; Karimi G
    Drug Res (Stuttg); 2015 Mar; 65(3):119-24. PubMed ID: 24623031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major.
    Navard SH; Rezvan H; Haddad MHF; Ali SA; Nourian A; Eslaminejad MB; Behmanesh MA
    J Glob Antimicrob Resist; 2020 Dec; 23():243-250. PubMed ID: 32977079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryotherapy of cutaneous leishmaniasis caused by
    Shaddel M; Sharifi I; Karvar M; Keyhani A; Baziar Z
    J Vector Borne Dis; 2018; 55(1):42-46. PubMed ID: 29916447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the
    Azadi R; Alipour-Talesh G; Yazdanpanah MJ; Alavizadeh SH; Maleki M; Banihashemi M; Jaafari MR
    J Vector Borne Dis; 2020; 57(1):78-84. PubMed ID: 33818460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical photodynamic therapy with chloroaluminum phthalocyanine liposomes is as effective as systemic pentavalent antimony in the treatment of experimental cutaneous leishmaniasis.
    Lopes SC; Silva RA; Novais MV; Coelho LD; Ferreira LA; Souza PE; Tedesco A; Azevedo RB; Aguiar MG; Oliveira MC
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():210-215. PubMed ID: 31454712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO/IR/75/ER).
    Mohtasebi S; Mohebali M; Elikaee S; Akhoundi B; Foroushani AR; Teimouri A; Yarizadeh H
    Parasitol Res; 2019 Sep; 118(9):2669-2678. PubMed ID: 31278518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.
    Borborema SE; Osso JA; Andrade HF; Nascimento Nd
    Mem Inst Oswaldo Cruz; 2013 Aug; 108(5):623-30. PubMed ID: 23903979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
    Bahrami S; Esmaeilzadeh S; Zarei M; Ahmadi F
    Parasitol Res; 2015 Dec; 114(12):4617-24. PubMed ID: 26346452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice.
    Brustolin AÁ; Franzói NM; Ramos-Milaré ÁCFH; Tanoshi CA; Mota CA; Demarchi IG; Lonardoni MVC; Verzignassi Silveira TG
    Exp Parasitol; 2022; 236-237():108259. PubMed ID: 35427563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.